Relazione di Ida Martinelli et al

More documents

Recommendations

Info

23. Girolami A, Tormene D, Gavasso S, Bertolo C, Girolami B. Long termuse of oral contraceptives without thrombosis in patients with FV Leidenpolymorphism: a study of 37 patients (2 homozygous and 35 heterozygous). JThromb Thrombolysis 2004; 17:145-924. Legnani C, Cini M, Cosmi B, Poggi M, Boggian O, Palareti G. Risk ofdeep vein thrombosis: interaction between oral contraceptives and high factorVIII levels. Haematologica 2004; 89:1347-51.25. Poka R, Vad S, Lakos G, Bereczki Z, Kiss E, Sipka S. Increased titer ofanti-beta2-glycoprotein I IgG antibody among factor V Leiden carriers duringoral contraceptive use. Contraception 2004; 69:27-3026. Cosmi B, Legnani C, Bernardi F, Coccheri S, Palareti G. Role of familyhistory in identifying women with thrombophilia and higher risk of venousthromboembolism during oral contraception. Arch Intern Med 2003;163:1105-9.27. van Hylckama Vlieg, Rosendaal FR. Interaction between oralcontraceptive use and coagulation factor levels in deep venous thrombosis. JThromb Haemost 2003; 1:2186-9028. Legnani C, Palareti G, Guazzaloca G, Cosmi B, Lunghi B, Bernardi F,Cocchieri S. Venous thromboembolism in young women; role of thrombophilicmutations and oral contraceptive use. Eur Heart J 2002; 3:984-90.29. Santamaria A, Mateo J, Oliver A, Menendez B, Souto JC, Borrell M, etal. Risk of thrombosis associated with oral contraceptives of women from 97families with inherited thrombophilia: high risk of thrombosis in carriers of theG20210A mutation of the prothrombin gene. Haematologica 2001; 86:965-7130. Aznar J, Vaya A, Estelles A, Mira Y, Segui R, Villa P, et al. Risk of venousthrombosis in carriers of the prothrombin G20210A variant and factor V Leidenand their interaction with oral contraceptives. Haematologica 2000; 85:1271-631. Spannagl M, Heinemann LA, Schramm W. Are factor V Leiden carrierswho use oral contraceptives at estreme risk for venous thromboembolism? EurJ Contracept Reprod Health Care 2000; 5:105-11232. Bloemenkamp KW, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP.Venous thrombosis, oral contraceptives and high factor VIII levels. ThrombHaemaost 1999; 82:1024-733. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interactionbetween the G20210A mutation of the prothrombin gene and oralcontraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol1999; 19:700-3
34. Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Does use of hormonalcontraceptives among women with thrombogenic mutations increase their riskof venous thromboembolism? A systematic review. Contraception 2006;73:166-78.35. Wu O, Robertson L, Langhorne P, Twaddle S, Lowe GD, Clark P et al.Oral contraceptives, hormone replacement therapy, thrombophilias and risk ofvenous thromboembolism: a systematic review. The Thrombosis: Risk andEconomic Assessment of Thrombophilia Screening (TREATS) Study. ThrombHaemost 2005; 94:17-25.36. Welker GC, Lookinland S, Tiedeman ME, Beckstrand RL. The role ofgenetics in the risk of thromboembolism: prothrombin 20210A and oralcontraceptive therapy. J Am Acad Nurse Pract 2004; 16:106-115.37. de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-controlstudy of risk of cerebral sinus thrombosis in oral contraceptive users and incarriers of hereditary prothrombotic conditions. The Cerebral Venous SinusThrombosis Group. BMJ 1998; 316:589-9238. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High riskof cerebral-vein thrombosis in carriers of a prothrombin gene mutation and inusers of oral contraceptives. N Engl J Med 1998; 338:1793-739. Dentali F, Crowther M, Ageno W. Thrombophilic abnormalities, oralcontraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood2006; 107:2766-73.40. Petitti DB, Sidney S, Quesenberry CP, Jr., Bernstein A. Incidence ofstroke and myocardial infarction in women of reproductive age. Stroke 1997;28:280-341. Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oralcontraceptives: A meta-analysis. JAMA 2000; 284:72-8.42. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association betweenthe current use of low-dose oral contraceptives and cardiovascular arterialdisease: a meta-analysis. J Clin Endocrinol Metab 2005; 90:3863-70.43. Chan WS, Ray J, Wai EK, Ginsburg S, Hannah ME, Corey PN, GinsbergJS. Risk of stroke in women exposed to low-dose oral contraceptives: a criticalevaluation of the evidence. Arch Intern Med 2004; 164:741-7.
Page 1 and 2: Incidenza di trombosi in età ferti
Page 3 and 4: di estrogeno < 50 μg. Poiché i pr
Page 5 and 6: L’aumento del rischio di TE arter
Page 7: 12. Jick H, Jick SS, Gurewich V, My
Page 11 and 12: Silverstein et al,1998 [6]Studio di
Page 13 and 14: Cosmi et al,2003 [26]Studio di coor
Page 15 and 16: de Bruijn et al.1998 [37]Studio cas
Page 17 and 18: Battaglioli etal, 2007 [15]Revision
Page 19: Tabella 3.Revisioni sistematiche e

Relazione di Ida Martinelli et al

Create successful ePaper yourself

Delete template?

Save as template?